Jolanda Howe - 01 Jul 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
SVP, GLOBAL CONTROLLER
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
01 Jul 2025
Net transactions value
-$50,624
Form type
4
Filing time
03 Jul 2025, 18:48:47 UTC
Previous filing
19 Mar 2025
Next filing
08 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Howe Jolanda SVP, GLOBAL CONTROLLER C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY /s/ Judit Ryvkin, Attorney-in-Fact 03 Jul 2025 0001974200

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise +1,041 +43% 3,467 01 Jul 2025 Direct F1
transaction MIRM Common Stock Sale $27,213 -564 -16% $48.25 2,903 02 Jul 2025 Direct F2
transaction MIRM Common Stock Sale $23,411 -477 -16% $49.08 2,426 03 Jul 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Restricted Stock Units Options Exercise $0 -1,041 -100% $0.000000 0 01 Jul 2025 Common Stock 1,041 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
F2 Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F3 Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 16, 2024.
F4 The restricted stock units vest in a series of three successive equal annual installments beginning July 1, 2023.